Contraception for adolescents

Pediatrics

Volumn 134, Issue 4, 2014, Pages e1244-e1256

  Braverman, Paula K ^a   Adelman, William P ^a   Alderman, Elizabeth M ^a   Breuner, Cora C ^a   Levine, David A ^a   Marcell, Arik V ^a   O'Brien, Rebecca F ^a  

^a NONE

Author keywords

Adolescent; Birth control; Contraception; Contraceptive implant; Contraceptive injection; Intrauterine device; Oral contraceptive pills

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; SPERMICIDAL AGENT; ULIPRISTAL;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADOLESCENT PREGNANCY; APPLICATION SITE HYPERPIGMENTATION; APPLICATION SITE IRRITATION; COITUS INTERRUPTUS; CONDOM; CONTACT DERMATITIS; CONTRACEPTIVE BEHAVIOR; CONTRACEPTIVE PATCH; COPPER INTRAUTERINE DEVICE; DISABLED PERSON; EMERGENCY CONTRACEPTION; EVIDENCE BASED MEDICINE; FEMALE; FEMALE STERILIZATION; GOOD CLINICAL PRACTICE; GRAFT RECIPIENT; HAIR LOSS; HEADACHE; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAUTERINE CONTRACEPTIVE DEVICE; LIBIDO DISORDER; MALE; MALE STERILIZATION; MASTALGIA; MEDICAL SOCIETY; MENSTRUAL IRREGULARITY; NAUSEA; OBESITY; PEDIATRICIAN; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SEXUAL ABSTINENCE; SEXUAL COUNSELING; SIDE EFFECT; UNITED STATES; UNWANTED PREGNANCY; UTERINE CERVIX CAP; WEIGHT GAIN; CONTRACEPTION; EPIDEMIOLOGY; HEALTH INSURANCE; PATIENT COMPLIANCE; PEDIATRICS; PREGNANCY; PROCEDURES; PSYCHOLOGY; SEXUAL BEHAVIOR; STANDARDS; TRENDS; UNPLANNED PREGNANCY;

ADOLESCENT; ADOLESCENT BEHAVIOR; CONTRACEPTION; FEMALE; HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT; HEALTH POLICY; HUMANS; MALE; PATIENT COMPLIANCE; PEDIATRICS; PREGNANCY; PREGNANCY, UNPLANNED; SEXUAL BEHAVIOR; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84925348498     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-2299     Document Type: Review

References (154)

1. Martinez G, Copen CE, Abma JC. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006-2010 national survey of family growth. Vital Health Stat 23. 2011; (31):1-35
2. Kost K, Henshaw S, Carlin L. US Teenage Pregnancies, Births and Abortions: National and State Trends and Trends by Race and Ethnicity. New York, NY: Guttmacher Institute; 2010
3. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011;84(5):478-485
4. Ott MA, Rosenberger JG, McBride KR, Woodcox SG. How do adolescents view health? Implications for state health policy. J Adolesc Health. 2011;48(4):398-403
5. Jones RK, Biddlecom AE. The more things change...: the relative importance of the internet as a source of contraceptive information for teens. Sex Res Soc Policy. 2011;8(1):27-37
6. Institute of Medicine, Committee on Preventive Services for Women. Clinical Preventive Services for Women: Closing the Gaps. Washington, DC: National Academies Press; 2011
7. Health Resources and Services Administration. Women's Preventive Services: Required Health Plan Coverage Guidelines. Rockville, MD: Health Resources and Services Administration; 2012
8. The Patient Protection and Affordable Care Act. Pub L No. 111-148 (2010). Available at: www.dol.gov/ebsa/healthreform/. Accessed January 13, 2014
9. Ford C, English A, Sigman G. Confidential Health Care for Adolescents: position paper for the society for adolescent medicine. J Adolesc Health. 2004;35(2):160-167. Available at: www.adolescenthealth.org/SAHM-Main/media/Advocacy/Positions/Aug-04-Confidential-Health-Care-for-Adolescents.pdf. Accessed June 22, 2014
10. American College of Obstetricians and Gynecologists. Guidelines for Adolescent Health Care. Washington, DC: American College of Obstetricians and Gynecologists; 2011
11. American Academy of Pediatrics, Committee on Adolescence. Policy statement: achieving quality health services for adolescents. Pediatrics. 2008;121(6):1263-1270. Available at: http://pediatrics.aappublications.org/content/121/6/1263.full.pdf+html. Accessed June 22, 2014
12. Center for Adolescent Health and the Law. State Minor Consent Laws: A Summary. 3rd ed. Chapel Hill, NC: Center for Adolescent Health and the Law; 2010
13. Guttmacher Institute. An overview of minors' consent law. State policies in brief as of June 1, 2014. Available at: www.guttmacher.org/statecenter/spibs/spib-MACS.pdf. Accessed June 20, 2014
14. English A, Ford CA. The HIPAA privacy rule and adolescents: legal questions and clinical challenges. Perspect Sex Reprod Health. 2004;36(2):80-86
15. Spooner SA; Council on Clinical Information Technology, American Academy of Pediatrics. Special requirements of electronic health record systems in pediatrics. Pediatrics. 2007;119(3):631-637 http://pediatrics.aappublications.org/content/119/3/631.full.pdf+html. Accessed June 22, 2014
16. Council on Clinical Information Technology. Health information technology and the medical home. Pediatrics. 2011;127(5):978-982. Available at: http://pediatrics.aappublications.org/content/127/5/978.full?sid=f3089a2a-b98c-4046-99c3-4e5386ef6e20. Accessed June 22, 2014
17. Reddy DM, Fleming R, Swain C. Effect of mandatory parental notification on adolescent girls' use of sexual health care services. JAMA. 2002;288(6):710-714
18. Zabin LS, Stark HA, Emerson MR. Reasons for delay in contraceptive clinic utilization. Adolescent clinic and nonclinic populations compared. J Adolesc Health. 1991;12(3):225-232
19. Guldi M. Fertility effects of abortion and birth control pill access for minors. Demography. 2008;45(4):817-827
20. Zavodny M. Fertility and parental consent for minors to receive contraceptives. Am J Public Health. 2004;94(8):1347-1351
21. Lehrer JA, Pantell R, Tebb K, Shafer MA. Forgone health care among U.S. adolescents: associations between risk characteristics and confidentiality concern. J Adolesc Health. 2007;40(3):218-226
22. Dempsey AF, Singer DD, Clark SJ, Davis MM. Adolescent preventive health care: what do parents want? J Pediatr. 2009;155 (5):689.e1-694.e1
23. Jones RK, Purcell A, Singh S, Finer LB. Adolescents' reports of parental knowledge of adolescents' use of sexual health services and their reactions to mandated parental notification for prescription contraception. JAMA. 2005;293(3):340-348
24. Hagan JF, Shaw JS, Duncan PM, eds. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents. Elk Grove Village, IL: American Academy of Pediatrics; 2008. Available at: http://brightfutures.aap.org/pdfs/Guidelines-PDF/18-Adolescence.pdf. Accessed June 22, 2014
25. Centers for Disease Control and Prevention. A Guide to Taking a Sexual History. Atlanta, GA: Centers for Disease Control and Prevention; 2005. Available at: www.cdc.gov/std/treatment/SexualHistory.pdf. Accessed June 22, 2014
26. Blum RW. Healthy youth development as a model for youth health promotion. A review. J Adolesc Health. 1998;22(5):368-375
27. Ott MA, Labbett RL, Gold MA. Counseling adolescents about abstinence in the office setting. J Pediatr Adolesc Gynecol. 2007;20(1):39-44
28. American Academy of Pediatrics, Committee on Adolescence. Technical report: contraception for adolescents. Pediatrics. 2014; (in press)
29. Brückner H, Bearman P. After the promise: the STD consequences of adolescent virginity pledges. J Adolesc Health. 2005;36(4):271-278
30. Pinkerton SD. A relative risk-based, disease-specific definition of sexual abstinence failure rates. Health Educ Behav. 2001;28(1):10-20
31. Committee on Adolescence. Office-based care for lesbian, gay, bisexual, transgender, and questioning youth. Pediatrics. 2013;132(1):198-203. Available at: http://pediatrics.aappublications.org/content/132/1/198.full.pdf. Accessed June 22, 2014
32. Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS. Contraceptive Technology. 20th rev ed. Valley Stream, NY: Ardent Media; 2011
33. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008;13(suppl 1):4-12
34. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception. 2006;74(4):287-289
35. Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception. 2009;80(6):527-532
36. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012;120(4):983-988
37. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep. 2010;59(RR-4):1-6. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a1.htm?s-cid=rr5904a1-e. Accessed June 22, 2014
38. Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. Obstet Gynecol. 2011;117(5):1114-1121
39. Kapp N, Curtis K, Nanda K. Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception. 2010;82(1):17-37
40. Bayer HealthCare Pharmaceuticals. Skyla package insert. Wayne, NJ: Bayer Health- Care Pharmaceuticals; 2013. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Skyla-PI.pdf. Accessed January 13, 2014
41. Bayer HealthCare Pharmaceuticals. Mirena package insert. Wayne, NJ: Bayer Health-Care Pharmaceuticals; 2013. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Mirena-PI.pdf. Accessed January 13, 2014
42. Teva Women's Health Inc/Teva Pharmaceuticals. Paragard package insert. Sellersville, PA: Teva Woman's Health Inc/Teva Pharmaceuticals; 2011. Available at: http://paragard.com/Pdf/ParaGard-PI.pdf. Accessed June 22, 2014
43. Trussell J. Update on and correction to the cost-effectiveness of contraceptives in the United States. Contraception. 2012;85(6):611
44. Committee on Adolescence. Emergency contraception. Pediatrics. 2012;130(6):1174-1182
45. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345(8):561-567
46. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility: follow-up after participation in a randomized clinical trial. Contraception. 2007;75(2):88-92
47. Penney G, Brechin S, de Souza A, et al; Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC guidance (January 2004). The copper intrauterine device as long-term contraception. J Fam Plann Reprod Health Care. 2004;30(1):29-41, quiz 42
48. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception. 2006;73(2):145-153
49. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339(8796):785-788
50. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 121: Long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2011;118(1):184-196
51. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet. 2000;356(9234):1013-1019
52. Centers for Disease Control and Prevention. US selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd Edition. MMWR Recomm Rep. 2013;62(RR-5):1-60
53. Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Stanwood NL. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev. 2010; (5):CD003036
54. Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. Contraception. 2009;80(4):327-336
55. American College of Obstetricians and Gynecologists. Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. ACOG committee opinion no. 450. Obstet Gynecol. 2009;114(6):1434-1438
56. Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2010;116(5):1079-1087
57. Ogburn JA, Espey E, Stonehocker J. Barriers to intrauterine device insertion in post-partum women. Contraception. 2005;72(6):426-429
58. Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Contraception. 2009;79(6):418-423
59. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod. 2006;21(10):2612-2616
60. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004;69(5):407-412
61. Bayer LL, Jensen JT, Li H, Nichols MD, Bednarek PH. Adolescent experience with intrauterine device insertion and use: a retrospective cohort study. Contraception. 2012;86(5):443-451
62. Alton TM, Brock GN, Yang D, Wilking DA, Hertweck SP, Loveless MB. Retrospective review of intrauterine device in adolescent and young women. J Pediatr Adolesc Gynecol. 2012;25(3):195-200
63. Godfrey EM, Memmel LM, Neustadt A, et al. Intrauterine contraception for adolescents aged 14-18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T 380A. Contraception. 2010;81(2):123-127
64. Paterson H, Ashton J, Harrison-Woolrych M. A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. Contraception. 2009;79(6):433-438
65. Pillai M, O'Brien K, Hill E. The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning disabilities. BJOG. 2010;117(2):216-221
66. Toma A, Jamieson MA. Revisiting the intrauterine contraceptive device in adolescents. J Pediatr Adolesc Gynecol. 2006;19(4):291-296
67. Lara-Torre E, Spotswood L, Correia N, Weiss PM. Intrauterine contraception in adolescents and young women: a descriptive study of use, side effects, and compliance. J Pediatr Adolesc Gynecol. 2011;24(1):39-41
68. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80(1):7-17
69. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med. 1996;41(5 suppl):419-427
70. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology. 1999;52(9):1917-1918
71. de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception. 1997;56(5):313-316
72. Manchikanti A, Grimes DA, Lopez LM, Schulz KF. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev. 2007; (2):CD006261
73. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception. 2009;80(2):113-118
74. Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception. 2006;74(3):234-238
75. Hubacher D, Goco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. Contraception. 1999;60(6):345-351
76. Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception. 2001;63(3):143-146
77. Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstet Gynecol. 2011;117(4):793-797
78. Le YC, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet Gynecol. 2009;114(2 pt 1):279-284
79. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health. 1999;24(6):433-436
80. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med. 2006;160(1):40-45
81. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (DepoProvera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1996;129(5):671-676
82. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004;17(1):17-21
83. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35(6):434-441
84. Pfizer. DepoProvera 150 mg and Depo SubQ Provera 104 package inserts. Cambridge, MA: Pfizer; 2005
85. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159(2):139-144
86. Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010;81(4):281-291
87. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008;112(4):788-799
88. US Pharmaceuticals/Pfizer Inc. Letter to health care professionals. November 18, 2004. Available at: www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM1-66395.pdf. Accessed January 13, 2014
89. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion no. 415: depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008;112(3):727-730
90. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2010. Available at: www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-calciumand-vitamin-D.aspx
91. Braverman PK, Breech L; Committee on Adolescence. American Academy of Pediatrics. Clinical report: gynecologic examination for adolescents in the pediatric office setting. Pediatrics. 2010;126(3):583-590. Available at: http://pediatrics.aappublications.org/content/126/3/583.full.pdf+html. Accessed June 22, 2014
92. Trenor CC III, Chung RJ, Michelson AD, et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011;127(2):347-357
93. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344(20):1527-1535
94. Walker ID. Venous and arterial thrombosis during pregnancy: epidemiology. Semin Vasc Med. 2003;3(1):25-32
95. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697-706
96. Dickey R. Managing Contraceptive Pill Patients. Fort Collins, CO: EMIS Inc Medical Publishers; 2010
97. Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception. 2011;83(1):16-29
98. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23. 2010; (29):1-44
99. Faculty of Sexual and Reproductive Healthcare, Royal College of Obstetricians and Gynaecologists. Faculty of Sexual and Reproductive Healthcare Clinical Guidance: Combined Hormonal Contraception. London, UK: Faculty of Sexual and Reproductive Healthcare, Royal College of Obstetricians and Gynaecologists; October 2011. Updated August 2012. Available at: www.fsrh.org/pdfs/CEUGuidanceCombined-HormonalContraception.pdf. Accessed January 13, 2014
100. Mansour D. Revision of the "missed pill" rules. J Fam Plann Reprod Health Care. 2011;37(3):128-131
101. Sucato GS, Gold MA. Extended cycling of oral contraceptive pills for adolescents. J Pediatr Adolesc Gynecol. 2002;15(5):325-327
102. Sucato GS, Gerschultz KL. Extended cycle hormonal contraception in adolescents. Curr Opin Obstet Gynecol. 2005;17(5):461-465
103. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin no. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107(6):1453-1472
104. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95(3):385-389
105. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16(3):469-475
106. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100(3):585-593
107. Edwardson J, Jamshidi R. The contraceptive vaginal ring. Semin Reprod Med. 2010;28(2):133-139
108. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39(3):233-242
109. Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception - oral versus intravaginal - on the sexual life of women and their partners. Hum Reprod. 2005;20(4):1100-1106
110. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol. 2004;104(3):555-563
111. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168-174
112. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2 pt 1):339-346
113. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010;81(5):408-413
114. Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol. 2005;18(2):85-90
115. Rubinstein ML, Halpern-Felsher BL, Irwin CE Jr. An evaluation of the use of the transdermal contraceptive patch in adolescents. J Adolesc Health. 2004;34(5):395-401
116. Stricker T, Sennhauser FH. Allergic contact dermatitis due to transdermal contraception patch. J Pediatr. 2006;148(6):845
117. Audet MC, Moreau M, Koltun WD, et al; ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001;285(18):2347-2354
118. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77(2 Suppl 2):S13-S18
119. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82(6):454-461
120. Gallo MF, Steiner MJ, Warner L, et al. Self-reported condom use is associated with reduced risk of chlamydia, gonorrhea, and trichomoniasis. Sex Transm Dis. 2007;34(10):829-833
121. Warner L, Macaluso M, Newman D, et al. Condom effectiveness for prevention of C trachomatis infection. Sex Transm Infect. 2006;82(3):265
122. Paz-Bailey G, Koumans EH, Sternberg M, et al. The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents. Arch Pediatr Adolesc Med. 2005;159(6):536-542
123. Niccolai LM, Rowhani-Rahbar A, Jenkins H, Green S, Dunne DW. Condom effectiveness for prevention of Chlamydia trachomatis infection. Sex Transm Infect. 2005;81(4):323-325
124. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002; (1):CD003255
125. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med. 2009;169(13):1233-1240
126. Stanaway JD, Wald A, Martin ET, Gottlieb SL, Magaret AS. Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition. Sex Transm Dis. 2012;39(5):388-393
127. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354(25):2645-2654
128. Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med. 2006;160(2):151-156
129. Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis. 2009;36(7):401-405
130. Matson PA, Adler NE, Millstein SG, Tschann JM, Ellen JM. Developmental changes in condom use among urban adolescent females: influence of partner context. J Adolesc Health. 2011;48(4):386-390
131. Bearinger LH, Sieving RE, Duke NN, McMorris BJ, Stoddard S, Pettingell SL. Adolescent condom use consistency over time: global versus partner-specific measures. Nurs Res. 2011;60(3 suppl):S68-S78
132. Kenyon DB, Sieving RE, Jerstad SJ, Pettingell SL, Skay CL. Individual, interpersonal, and relationship factors predicting hormonal and condom use consistency among adolescent girls. J Pediatr Health Care. 2010;24(4):241-249
133. American Academy of Pediatrics, Committee on Adolescence. Policy statement: condom use by adolescents. Pediatrics. 2013;132(5):973-981
134. Cheng L, Gülmezoglu AM, Piaggio G, Ezcurra E, Van Look PF. Interventions for emergency contraception. Cochrane Database Syst Rev. 2008; (2):CD001324
135. Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol. 2010;115(2 Pt 1):257-263
136. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375(9714):555-562
137. Rockoff JD. FDA reviewing efficacy of Plan B contraception in women over 165 pounds. The Wall Street Journal. November 25, 2013. Available at: http://online.wsj.com/news/articles/SB1000142405270-2304011304579220533719517944. Accessed January 13, 2014
138. Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84(4):363-367
139. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27(7):1994-2000
140. von Hertzen H, Piaggio G, Ding J, et al; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet. 2002;360(9348):1803-1810
141. Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol. 2004;103(2):359-373
142. US Food and Drug Administration. FDA approves Plan B One-Step emergency contraceptive for use without a prescription for all women of child-bearing potential. June 20, 2013. Available at: www.fda.gov/NewsEvents/Newsroom/Press-Announcements/ucm358082.htm. Accessed January 13, 2014
143. Ellertson C, Ambardekar S, Hedley A, Coyaji K, Trussell J, Blanchard K. Emergency contraception: randomized comparison of advance provision and information only. Obstet Gynecol. 2001;98(4):570-575
144. Meyer JL, Gold MA, Haggerty CL. Advance provision of emergency contraception among adolescent and young adult women: a systematic review of literature. J Pediatr Adolesc Gynecol. 2011;24(1):2-9
145. Bethell CD, Read D, Blumberg SJ, Newacheck PW. What is the prevalence of children with special health care needs? Toward an understanding of variations in findings and methods across three national surveys. Matern Child Health J. 2008;12(1):1-14
146. McRee AL, Haydon AA, Halpern CT. Reproductive health of young adults with physical disabilities in the U.S. Prev Med. 2010;51(6):502-504
147. Surís JC, Resnick MD, Cassuto N, Blum RW. Sexual behavior of adolescents with chronic disease and disability. J Adolesc Health. 1996;19(2):124-131
148. Akers AY, Lynch CP, Gold MA, et al. Exploring the relationship among weight, race, and sexual behaviors among girls. Pediatrics. 2009;124(5). Available at: www.pediatrics.org/cgi/content/full/124/5/e913
149. Mond J, van den Berg P, Boutelle K, Hannan P, Neumark-Sztainer D. Obesity, body dissatisfaction, and emotional well-being in early and late adolescence: findings from the project EAT study. J Adolesc Health. 2011;48(4):373-378
150. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012;120(1):21-26
151. Hormonal contraceptives for contraception in overweight or obese women. Obstet Gynecol. 2010;116(5):1206-1207
152. Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol. 2007;166(11):1306-1311
153. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 105: bariatric surgery and pregnancy. Obstet Gynecol. 2009;113(6):1306-1311
154. Hillman JB, Miller RJ, Inge TH. Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. J Womens Health (Larchmt). 2011;20(4):533-538